disrupt
local
airway
defens
mechan
often
increas
vulner
pneumonia
among
cancer
patient
breach
respiratori
epitheli
barrier
function
alter
mucociliari
clearanc
secret
may
occur
result
cancer
therapi
cellspecif
injuri
gener
mucos
medic
devic
nasogastr
endotrach
tube
hinder
coordin
glottic
activ
mucociliari
function
act
conduit
chronic
colon
pathogen
organ
numer
defect
local
innat
defens
also
describ
follow
chemotherapi
includ
derang
chemotaxi
phagocytosi
kill
alveolar
macrophag
resid
mast
cell
respiratori
epitheli
cell
tend
maintain
capac
elabor
inflammatori
mediat
follow
exposur
pathogen
despit
cytotox
chemotherapi
yet
primari
interfac
lower
respiratori
tract
pathogen
often
suscept
direct
injuri
mdr
pathogen
due
uniqu
exposur
cancer
patient
describ
concurr
alter
system
defens
mechan
impair
circul
leukocyt
innat
immun
system
exceedingli
common
neutrophil
exquisit
sensit
cytotox
effect
chemotherapi
may
induc
agranulocytosi
direct
myelotox
well
function
neutropenia
interf
phagocyt
chemotact
activ
cell
addit
neutrophil
dysfunct
result
radiat
therapi
corticosteroid
administr
common
cancerrel
disord
hypovolemia
prolong
hypoxemia
acidosi
poorli
control
hyperglycemia
frequent
problem
sever
neutropenia
defin
absolut
neutrophil
count
associ
refractori
lung
infect
caus
bacteri
fungal
organ
addit
rapid
onset
neutropenia
delay
neutrophil
recoveri
play
role
infect
sever
patient
febril
neutropenia
present
pulmonari
infiltr
infect
remain
frequent
caus
radiograph
abnorm
patient
absenc
consolid
infiltr
chest
radiograph
exclud
evolv
occult
pneumonia
particularli
set
profound
neutropenia
sever
pneumonia
includ
de
novo
infect
exacerb
chronic
lung
infect
also
aris
set
neutropenia
gramneg
bacilli
gnb
includ
enterobacteriacea
klebsiella
escherichia
coli
citrobact
serretia
proteu
spp
predomin
sourc
pneumonia
associ
neutropen
fever
mdr
gramposit
bacteria
methicillinresist
staphylococcu
aureu
mrsa
extend
spectrum
betalactamaseproduc
enterobacteriacea
also
frequent
cultur
set
neutropen
pneumonia
incid
pulmonari
infect
caus
gramposit
bacteria
aureu
streptococcu
spp
includ
streptococcu
pneumonia
decreas
past
three
decad
gramneg
pneumonia
particularli
caus
pseudomona
spp
becom
increas
sourc
lifethreaten
necrot
lung
infect
fig
nonfer
gramneg
bacteria
nfgnb
stenotrophomona
maltophilia
achromobact
alcaligen
speci
also
increas
recent
year
often
lead
difficulttotreat
infect
case
almost
popul
aspir
infect
materi
remain
predomin
mechan
entri
lower
respiratori
tract
infect
among
cancer
patient
howev
hematogen
dissemin
repres
uniqu
common
sourc
pneumonia
among
cancer
patient
bacteremia
febril
neutropen
patient
may
present
obviou
primari
site
origin
initi
antimicrobi
therapi
febril
neutropenia
patient
pulmonari
infiltr
broad
spectrum
provid
antimicrobi
activ
drugresist
strain
aureu
pseudomona
aeruginosa
earli
deescal
therapi
may
attempt
patient
demonstr
prompt
clinic
respons
granulocyt
recoveri
occur
expect
occur
near
futur
especi
pathogen
identifi
deescal
undertaken
caution
highrisk
patient
poor
clinic
respons
antimicrobi
therapi
persist
sever
andor
longstand
granulocytopenia
patient
continu
system
immunosuppress
therapi
addit
neutropenia
cytotox
antineoplast
therapi
hematolog
malign
may
caus
sever
depress
humor
cellmedi
adapt
immun
result
inadequ
immunoglobulin
product
andor
varieti
defect
b
cellmedi
defect
exampl
immunoglobulin
dyscrasia
associ
hypogammaglobulinemia
defect
opson
owe
asplenia
frequent
among
patient
certain
type
lymphoreticular
malign
multipl
myeloma
chronic
lymphocyt
leukemia
waldenstom
macroglobulinemia
hypocomplementemia
associ
asplenia
may
lead
uncheck
prolifer
encapsul
organ
requir
opson
complement
elimin
furthermor
defect
antibodydepend
lymphocyt
cytolyt
activ
may
allow
fulmin
parasit
infect
reduc
cell
number
activ
frequent
find
among
patient
hodgkin
diseas
hairi
cell
leukemia
adult
tcell
leukemia
lymphocyt
leukemia
graftversushost
diseas
gvhd
addit
viral
ill
antineoplast
agent
immunosuppress
drug
eg
fludarabin
inhibitor
antithymocyt
globulin
calcinneurin
inhibitor
tacrolimu
glucocorticosteroid
may
depress
cellular
immun
induc
profound
lymphopenia
andor
interrupt
activ
tcell
inflammatori
signal
transduct
pathway
patient
cellular
immun
dysfunct
increas
risk
infect
due
intracellular
organ
listeria
monocytogen
salmonella
spp
legionella
spp
pneumocysti
jiroveci
toxoplasma
gondii
invas
pulmonari
mycos
opportunist
virus
due
human
cytomegaloviru
human
varicellazost
viru
thu
virtual
everi
compon
normal
host
immun
may
affect
untoward
manner
cancer
treatment
sever
oftentim
protract
immun
suppress
follow
encourag
develop
unusu
intract
infect
specif
pathogen
caus
pneumonia
commonli
associ
depress
particular
immun
defect
list
tabl
communityacquir
pneumonia
cap
cap
defin
infecti
diseas
societi
america
idsa
american
thorac
societi
at
refer
radiograph
clinic
develop
pneumonia
patient
hospit
resid
nurs
home
day
prior
onset
symptom
meet
criteria
hcap
distinct
cap
nosocomi
pneumonia
remain
import
allow
predict
like
pathogen
permit
prognost
estim
base
epidemiolog
descript
underli
caus
consequ
distinct
provid
framework
decis
regard
diagnost
evalu
empir
antimicrobi
therapi
cancer
patient
frequent
expos
healthcar
set
inpati
outpati
thu
pneumonia
cancer
patient
often
defin
hospitalacquir
pneumonia
hap
healthcareassoci
pneumonia
hcap
rather
cap
etiolog
spectrum
bacteri
pathogen
caus
cap
among
cancer
patient
mildtomoder
immunosuppress
similar
patient
cancer
histori
howev
clinic
insignific
microbi
inoculum
gener
popul
may
caus
sever
infect
among
patient
underli
malign
pneumonia
remain
commonli
identifi
pathogen
frequent
caus
lethal
cap
superinfect
mdr
organ
emerg
problem
complic
manag
cap
aureu
nontyp
haemophilu
influenza
pseudomona
spp
gnb
may
also
caus
lifethreaten
cap
recent
nfgnb
stenotrophomona
burkholderia
chryseobacterium
achromobact
alcaligen
speci
increasingli
recogn
etiolog
agent
cap
nosocomi
infect
pyogen
neisseria
meningitidi
moraxella
catarrhali
also
caus
cap
less
frequent
incid
cap
associ
atyp
pathogen
mycoplasma
pneumonia
chlamydia
pneumonia
legionella
spp
vari
wide
patient
age
geograph
locat
viral
pneumonia
commonli
influenza
parainfluenza
adenovir
infect
sourc
cap
may
caus
sever
pneumonia
cancer
set
diagnosi
cap
base
recoveri
like
pathogen
otherwis
steril
sourc
blood
urin
pleural
fluid
isol
noncommens
organ
respiratori
secret
posit
result
select
serolog
test
although
util
gram
stain
cultur
expector
sputum
diagnosi
pneumonia
debat
year
care
procur
sputum
specimen
cytolog
confirm
lower
respiratori
sourc
appear
diagnost
use
particularli
obtain
initi
antimicrobi
therapi
earli
accur
diagnos
critic
success
outcom
although
treatment
withheld
diagnost
intervent
undertaken
antimicrobi
select
best
base
knowledg
infect
pathogen
avail
pneumonia
sever
underli
immun
statu
presenc
comorbid
condit
hospitalacquir
pneumonia
lung
infect
occur
h
hospit
admiss
patient
without
anteced
clinic
symptom
radiograph
find
suggest
pneumonia
refer
hap
hap
common
complic
patient
receiv
treatment
cancer
recent
at
idsa
recogn
hcap
distinct
entiti
within
spectrum
hap
ventilatorassoci
pneumonia
vap
hcap
includ
patient
hospit
acut
care
hospit
day
within
day
current
infect
patient
treat
hospit
hemodialysi
clinic
within
day
pneumonia
diagnosi
nurs
home
longterm
care
facil
resid
recipi
intraven
antibiot
chemotherapi
wound
care
within
day
current
infect
hap
hcap
vap
compris
major
pneumonia
cancer
set
spectrum
pathogen
hcap
close
resembl
lateonset
hap
vap
particularli
among
elderli
patient
thu
guidelin
manag
hcap
gener
overlap
hap
vap
nonimmunosuppress
solidorgan
cancer
patient
hap
often
seen
intens
care
unit
icu
fact
admiss
icu
increas
risk
pneumonia
patient
nearli
mani
icurel
hap
occur
among
patient
receiv
ventilatori
support
effect
vap
icu
length
stay
ventil
day
hospit
length
stay
well
document
etiolog
spectrum
microbi
pathogen
caus
hap
among
lowrisk
solidorgan
cancer
patient
recent
antibiot
exposur
similar
seen
gener
popul
h
influenza
pneumonia
aureu
enterobacteriacea
frequent
encount
mrsa
may
caus
refractori
hap
especi
among
patient
prior
communityacquir
mrsa
colon
antibiot
exposur
advanc
age
andor
prolong
ventilatori
support
protract
mechan
ventil
recent
antibiot
administr
also
associ
increas
rate
hap
caus
p
aeruginosa
acinetobact
baumanniicomplex
enterobact
spp
emerg
strain
mdr
nfgnb
maltophilia
burkholderia
cepacia
complex
alcaligen
achromobact
speci
may
difficult
treat
mortal
rate
associ
hap
due
mrsa
p
aeruginosa
disproportion
higher
caus
nosocomi
bacteri
pathogen
sever
neutropenia
remain
independ
predictor
hap
due
nfgnb
invas
fungal
diseas
sever
neutropen
patient
absolut
neutrophil
count
cellsl
difficult
treat
antimicrobi
therapi
alon
aerosol
antifung
immun
stimul
may
also
consid
context
polymicrobi
isol
mdr
pathogen
common
among
patient
hap
particularli
occur
late
complic
hospit
frequenc
multipl
organ
identifi
singl
respiratori
sampl
recent
evidencebas
guidelin
advoc
use
quantit
semiquantit
lower
respiratori
tract
cultur
obtain
either
bronchoscop
noninvas
part
initi
evalu
patient
suspect
hap
vap
hcap
empir
antibiot
select
hap
develop
within
day
admiss
target
pneumonia
aureu
includ
mrsa
streptococcu
spp
h
influenza
enterobacteriacea
patient
late
hap
occur
week
hospit
receiv
empir
antimicrobi
therapi
includ
coverag
mdrgnb
scope
altern
antimicrobi
choic
patient
refractori
slowtorespond
hospit
andor
ventilatoracquir
pneumonia
vap
base
institutiondepend
suscept
profil
pneumonia
caus
aspir
bronchial
obstruct
aspir
orogastr
content
mechan
obstruct
airway
may
creat
favor
milieu
pneumonia
caus
microaerophil
anaerob
bacteria
eg
peptostreptococcu
spp
varieti
factor
abnorm
swallow
function
alter
cough
reflex
impair
mucociliari
clearanc
alter
mental
statu
use
sedat
medic
chemotherapyinduc
mucos
supin
posit
gastroparesi
mechan
ventil
nasogastr
tube
feed
contribut
increas
predilect
aspir
cancer
set
pneumonia
associ
largevolum
aspir
gastric
content
typic
occur
late
find
acid
gastric
content
act
poor
medium
bacteri
growth
thu
initi
clinic
syndrom
follow
aspir
gastric
content
aris
direct
caustic
effect
acid
aspir
cell
alveolarcapillari
interfac
ie
chemic
pneumon
pneumonia
due
superimpos
bacteri
infect
occur
present
later
find
ard
respiratori
failur
death
may
rapidli
follow
aspir
oral
content
contrast
result
inhal
nonsteril
oropharyng
materi
clinic
present
often
insidi
diagnosi
commonli
infer
base
compat
patient
risk
profil
coupl
radiograph
evid
pneumonia
chest
radiograph
may
show
area
geograph
abnorm
correl
patient
posit
time
aspir
exampl
aspir
occur
patient
upright
posit
typic
local
basilar
segment
lower
lobe
wherea
superior
segment
lower
lobe
posterior
segment
upper
lobe
frequent
affect
follow
aspir
occur
supin
posit
major
pathogen
underli
nosocomi
versu
communityacquir
aspir
pneumonia
differ
substanti
portion
patient
microbiolog
diagnosi
may
establish
due
limit
yield
convent
anaerob
cultur
necessari
cultur
may
best
obtain
bronchoscop
use
protect
specimen
brush
protect
strategi
manag
patient
signific
lung
injuri
associ
aspir
gastric
content
includ
aggress
support
care
upper
airway
suction
pulmonari
toilet
necessari
posit
pressur
ventil
compris
mainstay
therapi
clearli
establish
role
corticosteroid
set
though
practic
prescrib
moder
highdos
prednisolon
uncommon
earli
aggress
antimicrobi
therapi
recommend
patient
pneumonia
secondari
aspir
oropharyng
content
antimicrobi
select
tailor
immun
statu
patient
set
aspir
occur
commun
vs
nosocomi
gener
broad
spectrum
target
gramneg
organ
without
anaerob
coverag
anaerob
coverag
consid
patient
periodont
diseas
putrid
sputum
evid
necrot
pneumonia
solid
tumor
involv
lung
may
caus
obstruct
airway
atelectasi
postobstruct
pneumonia
airway
obstruct
set
may
due
endobronchi
tumor
extralumin
mass
result
extrins
compress
conduct
airway
associ
pneumonia
tend
polymicrobi
natur
gnb
staphylococci
anaerob
may
requir
relief
obstruct
achiev
adequ
antimicrobi
effect
even
appropri
antibiot
select
often
rapidli
achiev
intervent
bronchoscop
techniqu
tumor
debulk
laser
electrocauteri
argon
plasma
coagul
without
stent
placement
endobronchi
brachytherapi
cryotherapi
appli
bronchoscop
well
often
excel
result
time
effect
gener
longer
form
strategi
chemoradi
therapi
similarli
effect
reliev
obstruct
effect
therapi
also
delay
rel
bronchoscop
debulk
sourc
pneumonia
lung
may
also
becom
infect
via
septic
emboli
aris
suppur
endovascular
bacteri
rare
fungal
infect
infect
intravascular
septic
deep
venou
thrombi
increasingli
recogn
potenti
sourc
infect
patient
cancer
radiograph
pattern
patient
distinct
includ
multicentr
pleomorph
lung
nodul
asymmetr
rel
small
thickwal
caviti
gener
appear
distinct
nonspecif
infiltr
associ
hematogen
dissemin
distant
site
infect
discuss
previous
nocardiosi
nocardia
asteroid
complex
includ
n
asteroid
sensu
stricto
n
farcinica
account
nearli
nocardia
infect
cancer
patient
gener
popul
risk
factor
nocardia
pneumonia
includ
profound
defici
cellular
immun
prolong
use
highdos
system
corticosteroid
especi
treatment
chronic
lung
diseas
presenc
gvhd
although
latter
two
risk
factor
often
seen
togeth
ie
steroid
treatment
gvhd
appear
independ
increas
risk
nodular
pulmonari
infiltr
common
radiograph
find
although
reticulonodular
diffus
infiltr
occasion
describ
solitari
nodul
associ
irregular
thickwal
caviti
mimic
invas
pulmonari
aspergillosi
histoplasmosi
necrot
cancer
chronic
bacteri
lung
abscess
also
report
fig
indol
nocardia
pneumonia
clinic
indistinguish
actinomycet
infect
pneumonia
caus
pulmonari
eumycet
infect
sever
immunosuppress
cancer
patient
refractori
leukemia
allogenen
hematopoet
stem
cell
transplant
hsct
may
present
pulmonari
nocardiosi
rapidli
progress
often
multifoc
form
norcardia
spontan
hemoptysi
wide
report
present
among
immunocompromis
patient
fig
brain
involv
common
preemptiv
evalu
recommend
diagnos
asymptomat
brain
abscess
set
pulmonari
diseas
trimethoprimsulfamethoxazol
mgkg
daili
effect
mani
nocardia
spp
retrospect
studi
suggest
improv
outcom
appropri
therapi
given
extend
period
time
month
yet
despit
antimicrobi
therapi
pulmonari
nocardiosi
carri
high
mortal
highrisk
cancer
patient
pulmonari
actinomycosi
typic
present
similar
manner
nocardiasi
though
sulfur
granul
describ
typic
sampl
former
infect
classic
cross
tissu
plan
pulmonari
infect
oftentim
involv
adjoin
pleura
may
erod
chest
wall
howev
isol
actinomycet
respiratori
tract
evalu
critic
patient
presenc
repres
oropharyng
contamin
tubercul
mycobacterium
tubercul
rare
caus
pulmonari
infect
develop
world
still
occasion
found
sever
immunosuppress
cancer
patient
foreignborn
individu
receiv
cancer
care
nonendem
region
world
patient
hodgkin
diseas
cancer
head
neck
lung
breast
consid
highest
risk
pulmonari
tubercul
infect
oncolog
center
unit
state
caus
reactiv
remot
acquir
latent
infect
pulmonari
tubercul
may
present
insidi
pneumonia
difficult
distinguish
actinomycet
eumycet
infect
patient
impair
tcell
respons
may
develop
rapidli
progress
tubercul
follow
virul
bacteri
infect
system
corticosteroid
therapi
independ
predictor
tubercul
reactiv
suboptim
respons
combin
antimicrobi
therapi
henc
diagnosi
tubercul
establish
everi
effort
made
discontinu
steroid
therapi
observ
hivinfect
patient
initi
therapi
highli
activ
antiretrovir
therapi
demonstr
clinic
worsen
tubercul
pneumonia
ie
immun
reconstitut
syndrom
tuberculousrel
lung
diseas
cancer
stem
cell
transplant
patient
may
infrequ
worsen
patient
immun
function
recov
nonetheless
minim
immun
suppress
essenti
clear
mycobacteria
nontubercul
mycobacteriosi
ntm
pulmonari
ntm
classic
caus
aviumintracellulara
complex
slowgrow
mycobacteria
opportunist
pathogen
lead
chronic
indol
lung
infect
unit
state
rapidli
grow
mycobacteria
abscessu
less
frequent
fortuitum
smegmati
goodii
emerg
less
frequent
caus
ntm
infect
diagnosi
pulmonari
ntm
remain
challeng
identif
mycobacteria
respiratori
cultur
sampl
may
result
colon
respiratori
tract
environment
contamin
causal
suggest
identif
ntm
steril
lower
respiratori
tract
sampl
coupl
nonspecif
clinic
featur
chronic
nonproduct
cough
exert
dyspnea
cough
may
occasion
becom
product
indic
underli
bronchiectasi
fever
night
sweat
weight
loss
pleurit
chest
pain
pleural
effus
seldom
seen
radiograph
featur
includ
upper
lobe
predomin
nonspecif
nodular
lesion
small
thinwal
caviti
chest
ct
find
demonstr
characterist
treeinbud
appear
may
also
seen
patient
chronic
infect
socal
ladi
windermer
syndrom
character
relaps
refractori
pulmonari
ntm
due
slowgrow
mycobacteria
may
seen
patient
defect
endogen
interferongamma
activ
ntm
pulmonari
infect
usual
insidi
although
rapidli
progress
diseas
seen
patient
profound
defect
helper
tcell
treatment
includ
least
two
antimicrobi
agent
mycobacterium
suscept
includ
rifampin
given
month
kansasii
antigen
similar
tubercul
caus
lung
diseas
clinic
radiograph
indistinguish
pulmonari
tubercul
endem
area
kansasii
infect
us
includ
urban
southeast
midwestern
state
due
associ
architectur
derang
possibl
impair
phagocytosi
alveolar
macrophag
pneumoconios
wellestablish
predispos
condit
ntm
infect
prolong
therapi
month
rifampin
plu
one
two
suscept
antimicrobi
recommend
pneumocysti
p
jiroveci
infect
primarili
seen
patient
mark
lymphocytopenia
cancer
patient
pneumocysti
pneumonia
present
slowli
progress
infect
accompani
nonproduct
cough
exert
dyspnea
hypoxemia
although
acut
rapidli
progress
form
rapidli
progress
respiratori
failur
report
ct
evid
perihilar
infiltr
may
mistaken
pneumon
caus
common
acquir
viral
infect
rsv
influenza
parainfluenza
type
cmv
earli
phase
infect
bronchoalveolar
lavag
typic
high
diagnost
yield
though
lung
biopsi
occasion
need
cancer
patient
typic
lower
fungal
burden
hivinfect
patient
highdos
trimethoprimsulfamethoxazol
given
day
treatment
choic
adjuv
system
corticosteroid
administ
patient
sever
hypoxemia
oral
atovaquon
parenter
pentamidin
may
given
patient
intoler
sulfacontain
regimen
invas
pulmonari
mycosi
invas
pulmonari
aspergillosi
common
fungal
pneumonia
cancer
patient
risk
factor
invas
pulmonari
aspergillosi
includ
prolong
week
sever
neutropenia
refractori
leukemia
allogen
hsct
gvhd
immunosuppress
therapi
highdos
system
corticosteroid
therapi
aspergillu
fumigatu
promin
group
although
amphotericin
bresist
terreu
recent
emerg
second
frequent
aspergillu
spp
cancer
patient
nearexponenti
rise
pulmonari
invas
fungal
infect
due
nonaspergillu
mold
fusarium
pseudallescheria
boydii
scedosporium
spp
dematiac
black
mold
often
suscept
convent
antifung
agent
pose
seriou
challeng
select
effect
empir
preemptiv
therapi
fever
cough
dyspnea
present
suggest
lung
infect
hemoptysi
uncommon
chest
imag
studi
frequent
nonspecif
though
ct
scan
may
reveal
highli
suggest
halo
sign
crescent
sign
case
pulmonari
mycosi
radiograph
find
time
present
peripher
pleuralbas
lung
nodul
sometim
thickwal
regular
irregular
caviti
fig
alveolar
hemorrhag
may
occasion
herald
invas
pulmonari
fungal
infect
declin
incid
endem
mycos
pulmonari
histoplasmosi
blastomycosi
coccidioidomycosi
well
cryptococcu
neoforman
infect
report
larg
attribut
effect
prophylaxi
fluconazol
immunosuppress
cancer
patient
incid
zygomycosi
hand
increas
recent
year
like
relat
increas
util
recent
avail
antifung
agent
voriconazol
concomit
declin
use
amphotericin
b
zygomycet
organ
typic
show
high
level
suscept
amphotericin
b
decreas
util
agent
rate
fungal
infect
institut
caus
zygomycosi
invas
aspergillosi
fusarium
speci
year
patientday
respect
definit
diagnosi
pulmonari
invas
fungal
infect
requir
demonstr
fungal
hypha
within
involv
lung
tissu
therefor
clinic
diagnosi
often
made
infer
thrombocytopenia
coagulopathi
often
render
biopsi
unsaf
import
note
isol
mold
patient
peripher
central
venou
blood
sampl
may
indic
dissemin
mycosi
even
sever
immunosuppress
allogen
hsct
recipi
similarli
isol
fungi
respiratori
sampl
may
misrepres
etiolog
underli
pulmonari
infiltr
therefor
current
consensu
invas
fungal
infect
diagnosi
includ
evalu
host
predispos
factor
prolong
granulocytopenia
highrisk
hsct
gvhd
immunosuppress
therapi
b
clinic
featur
less
often
seen
cancer
stem
cell
transplant
recipi
c
radiograph
featur
isol
pathogen
fungu
steril
respiratori
site
measur
fungal
antigen
serum
galactomannan
level
may
help
detect
pulmonari
mycosi
recent
studi
hsct
recipi
serum
galactomannan
level
diagnost
patient
diagnost
util
test
howev
markedli
compromis
set
antifung
therapi
newer
diagnost
test
includ
fungal
dna
amplif
steril
sampl
current
investig
need
clinic
valid
routin
use
recommend
treatment
pulmonari
mycosi
improv
consider
past
year
avail
voriconazol
primari
therapi
invas
pulmonari
aspergillosi
caspofungin
salvag
therapi
refractori
invas
aspergillosi
promis
addit
antifung
armamentarium
antifung
combin
may
prescrib
highrisk
cancer
patient
hsct
recipi
invas
mycosi
due
lack
prospect
random
trial
consensu
recommend
prefer
antifung
combin
preliminari
studi
use
variou
antifung
combin
hint
modest
superior
caspofungin
plu
voriconazol
hsct
recipi
invas
fungal
infect
reconstitut
immun
system
includ
recoveri
sever
granulocytopenia
remain
critic
determin
promot
resolut
invas
fungal
infect
donor
granulocyt
transfus
adjuv
recombin
cytokin
need
prospect
evalu
although
result
preliminari
observ
studi
among
highrisk
allogen
hsct
recipi
dissemin
mycosi
appear
promis
virus
human
cytomegaloviru
pneumonia
frequent
caus
opportunist
viral
complic
cancer
patient
defect
cellular
immun
pulmonari
varicellazost
viru
lung
infect
difficult
distinguish
cmv
pneumon
season
respiratori
virus
rsv
influenza
b
parainfluenza
type
adenoviru
also
caus
seriou
lower
respiratori
tract
infect
immunosuppress
cancer
patient
fever
nonproduct
cough
promin
nonspecif
featur
patient
extens
lung
involv
dyspnea
may
appear
earli
cours
infect
viral
antigen
detect
nasal
wash
tracheal
aspir
bronchial
specimen
frequent
use
determin
activ
viral
replic
chest
ct
scan
may
show
ground
glass
infiltr
despit
normal
convent
chest
radiograph
normal
chest
ct
scan
highrisk
hsct
recipi
suspect
viral
pneumon
exclud
possibl
infect
case
presenc
cmv
viremia
anoth
help
indic
determin
etiolog
pulmonari
process
isol
cmv
antigen
lower
respiratori
tract
secret
may
howev
necessarili
indic
pulmonari
infect
patient
cellular
immun
defect
may
intermitt
lowlevel
viral
replic
shed
viru
without
develop
endorgan
diseas
ganciclovir
foscarnet
commonli
prescrib
system
cmv
infect
antivir
combin
adjuv
immunoglobulin
ivig
therapi
associ
variabl
result
present
recommend
routin
use
human
metapneumoviru
hmpv
recent
recogn
seriou
pulmonari
pathogen
spectrum
hmpv
diseas
may
rang
mild
upper
respiratori
tract
infect
seriou
dissemin
infect
lead
respiratori
failur
enceph
ribavirin
use
success
intraven
ribavirin
may
consid
patient
lifethreaten
hmpv
diseas
miscellan
pulmonari
gondii
l
monocytogen
infect
lead
seriou
often
lifethreaten
complic
patient
profound
cellular
immun
dysfunct
diseas
characterist
describ
detail
elsewher
